Kiora updates pipeline; KIO-301 Phase 1b results expected 1H 2023

KIORA PHARMACEUTICALS INC

KIO-301 (RP) Phase 1b ABACUS trial first patient dosed Q4 2022; preliminary results expected 1H 2023.
KIO-101 (OPRA+) Phase 2 trial conditionally approved; first patient enrollment planned 1H 2023.
KIO-201 (PCED) Phase 2 trial fully enrolled Q4 2022; results and FDA registration dialogue expected 1H 2023.
Raised ~$20M gross in past 18 months; received $1.2M in R&D tax credits.
Appointed Melissa Tosca as EVP Finance; strengthened SEC reporting procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.